Results 141 to 150 of about 4,228,114 (275)
Next‐generation proteomics improves lung cancer risk prediction
Molecular Oncology, EarlyView.This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner +4 morewiley +1 more sourcePotential therapeutic targeting of BKCa channels in glioblastoma treatment
Molecular Oncology, EarlyView.This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk +4 morewiley +1 more sourceEffective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
Molecular Oncology, EarlyView.WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet +17 morewiley +1 more source\pi\pi scattering
, 2001 We demonstrate that, together with the available experimental information, chiral symmetry determines the low energy behaviour of the $\pi\pi$ scattering amplitude to within very small uncertainties. In particular, the threshold parameters of the S-, P-, D- and F-waves are predicted, as well as the mass and width of the $\rho$ and of the broad bump in ...Colangelo, G., Gasser, J., Leutwyler, H.openaire +1 more sourceAmplitude analysis of the decays $D^0\rightarrow\pi^+\pi^-\pi^+\pi^-$ and $D^0\rightarrow\pi^+\pi^-\pi^0\pi0$
Published by IOP Publ., Bristol [u.a.]Ablikim 麦, M. 迪娜, Achasov, M. N., Balossino, I., Gao 高, Yang 扬, Garbolino, S., Garzia, I., Ge 葛, P. T. 潘婷, Ge 葛, Z. W. 振武, Geng 耿, C. 聪, Gersabeck, E. M., Gilman, A., Goetzen, K., Gong 龚, L. 丽, Ban 班, Y. 勇, Gong 龚, W. X. 文煊, Gradl, W., Gramigna, S., Greco, M., Gu 顾, M. H. 旻皓, Gu 顾, Y. T. 运厅, Guan 关, C. Y. 春懿, Guan, Z. L., Guo 郭, A. Q. 爱强, Guo 郭, L. B. 立波, Bao 包, H.-R. 浩然, Guo 国, M. J. 梦娇, Guo 郭, R. P. 如盼, Guo 郭, Y. P. 玉萍, Guskov, A., Gutierrez, J., Han 韩, K. L. 坤霖, Han 韩, T. T. 婷婷, Hao 郝, X. Q. 喜庆, Harris, F. A., He 何, K. K. 凯凯, Batozskaya, V., He 何, K. L. 康林, Heinsius, F. H., Heinz, C. H., Heng 衡, Y. K. 月昆, Herold, C., Holtmann, T., Hong, P. C., Hou 侯, G. Y. 国一, Hou 侯, X. T. 贤涛, Hou 侯, Y. R. 颖锐, Begzsuren, K., Hou 侯, Z. L. 治龙, Hu 胡, B. Y. 碧颖, Hu 胡, H. M. 海明, Hu 胡, J. F. 继峰, Hu 胡, T. 涛, Hu 胡, Y. 誉, Huang 黄, G. S. 光顺, Huang 黄, K. X. 凯旋, Huang 黄, L. Q. 麟钦, Huang 黄, X. T. 性涛, Berger, N., Huang 黄, Y. P. 燕萍, Hussain, T., H\'olzken, F., H\'usken, N., in der Wiesche, N., Irshad, M., Jackson, J., Janchiv, S., Jeong, J. H., Ji 纪, Q. 全, Berlowski, M., Ji 姬, Q. P. 清平, Ji 季, W. 旺, Ji 季, X. B. 晓斌, Ji 季, X. L. 筱璐, Ji 吉, Y. Y. 钰瑶, Jia 贾, X. Q. 晓倩, Jia 贾, Z. K. 泽坤, Jiang 姜, D. 地, Jiang 姜, H. B. 候兵, Jiang 蒋, P. C. 沛成, Bertani, M., Jiang 姜, S. S. 赛赛, Jiang 蒋, T. J. 庭俊, Jiang 江, X. S. 晓山, Jiang 蒋, Y. 艺, Jiao 焦, J. B. 健斌, Jiao 焦, J. K. 俊坤, Jiao 焦, Z. 铮, Jin 金, S. 山, Jin 金, Y. 毅, Jing 荆, M. Q. 茂强, Bettoni, D., Jing 景, X. M. 新媚, Johansson, T., Kabana, S., Kalantar-Nayestanaki, N., Kang 康, X. L. 晓琳, Kang 康, X. S. 晓珅, Kavatsyuk, M., Ke 柯, B. C. 百谦, Khachatryan, V., Khoukaz, A., Bianchi, F., Kiuchi, R., Kolcu, O. B., Kopf, B., Kuessner, M., Kui 奎, X. 贤, Kupsc, A., K\'uhn, W., Lane, J. J., Larin, P., Lavezzi, L., Adlarson, P., Bianco, E., Lei 雷, T. T. 天天, Lei 雷, Z. H. 祚弘, Leithoff, H., Lellmann, M., Lenz, T., Li 李, C. 翠, Li 李, C. 聪, Li 李, C. H. 春花, Li 李, Cheng 澄, Li 李, D. M. 德民, Bortone, A., Li 李, F. 飞, Li 李, G. 刚, Li, H., Li 李, H. B. 海波, Li 李, H. J. 惠静, Li 李, H. N. 衡讷, Li 李, Hui 慧, Li 李, J. R. 嘉荣, Li 李, J. S. 静舒, Li 李, K. 科, Boyko, I., Li 李, L. J. 林健, Li 李, L. K. 龙科, Li 李, Lei 蕾, Li 李, M. H. 明浩, Li 李, P. R. 培荣, Li 李, Q. M. 启铭, Li 李, Q. X. 起鑫, Li 李, R. 燃, Li 李, S. X. 素娴, Li 李, T. 腾, Briere, R. A., Li 李, W. D. 卫东, Li 李, W. G. 卫国, Li 李, X. 旭, Li 李, X. H. 旭红, Li 李, X. L. 晓玲, Li 李, X. Y. 晓宇, Li 李, Y. G. 彦谷, Li 李, Z. J. 志军, Li 李, Z. X. 振轩, Liang 梁, C. 畅, Brueggemann, A., Liang 梁, H. 昊, Liang 梁, H. 浩, Liang 梁, Y. F. 勇飞, Liang 梁, Y. T. 羽铁, Liao 廖, G. R. 广睿, Liao 廖, L. Z. 龙洲, Liao 廖, Y. P. 一朴, Libby, J., Limphirat, A., Lin 林, D. X. 德旭, Cai 蔡, H. 浩, Lin 林, T. 韬, Liu 刘, B. J. 北江, Liu 刘, B. X. 宝鑫, Liu 刘, C. 成, Liu 刘, C. X. 春秀, Liu 刘, F. 芳, Liu 刘, F. H. 福虎, Liu 刘, Feng 峰, Liu 刘, G. M. 国明, Liu 刘, H. 昊, Cai 蔡, X. 啸, Liu 刘, H. B. 宏邦, Liu 刘, H. H. 欢欢, Liu 刘, H. M. 怀民, Liu 刘, Huihui 汇慧, Liu 刘, J. B. 建北, Liu 刘, J. Y. 晶译, Liu 刘, K. 凯, Liu 刘, K. Y. 魁勇, Liu 刘, Ke 珂, Liu 刘, L. 亮, Calcaterra, A., Liu 刘, L. C. 良辰, Liu 刘, Lu 露, Liu 刘, M. H. 美宏, Liu 刘, P. L. 佩莲, Liu 刘, Q. 倩, Liu 刘, S. B. 树彬, Liu 刘, T. 桐, Liu 刘, W. K. 维克, Liu 刘, W. M. 卫民 +199 moreopenaire +2 more sourcesMonitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer
Molecular Oncology, EarlyView.Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien +35 morewiley +1 more sourceATF4‐mediated stress response as a therapeutic vulnerability in chordoma
Molecular Oncology, EarlyView.We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs +11 morewiley +1 more sourceA subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy
Molecular Oncology, EarlyView.Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli +3 morewiley +1 more sourceDeveloping evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking +43 morewiley +1 more sourceProfile of diabetic patients accompanied by the pharmaceutical assistance of Piauí, Brazil
O Mundo da Saúde, 2018 Diabetes mellitus consists of a chronic disease that currently stands out for its associated morbidity and mortality. The therapy is based on the association of different drugs and requires a change in the habits of the patients.Renata Rodrigues de Oliveira Castelo Branco, Pablo Ricardo Barbosa Ferreira, Sean Telles Pereira, Éverton José Ferreira de Araújo, Amanda Mota Conceição, Flávia Mylla de Sousa Reis, Luís Mário Rezende Júnior, Pablo Ricardo Barbosa Ferreira +7 moredoaj